Glycans as cancer biomarkers

Barbara Adamczyk1, Tharmala Tharmalingam, Pauline M Rudd

  • 1Dublin-Oxford Glycobiology Laboratory, NIBRT-The National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland.

Summary

Serum glycoprotein changes, including fucosylation and sialylation, show promise as novel cancer biomarkers. Advanced glycan analysis and high-throughput platforms enable efficient biomarker discovery for improved cancer prognosis and monitoring.